BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36324112)

  • 1. A feline case of multiple myeloma treated with bortezomib.
    Tani H; Miyamoto R; Miyazaki T; Oniki S; Tamura K; Bonkobara M
    BMC Vet Res; 2022 Nov; 18(1):384. PubMed ID: 36324112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
    Maruyama D; Iida S; Ogawa G; Fukuhara N; Seo S; Miyazaki K; Yoshimitsu M; Kuroda J; Tsukamoto N; Tsujimura H; Hangaishi A; Yamauchi T; Utsumi T; Mizuno I; Takamatsu Y; Nagata Y; Minauchi K; Ohtsuka E; Hanamura I; Yoshida S; Yamasaki S; Suehiro Y; Kamiyama Y; Tsukasaki K; Nagai H
    Br J Haematol; 2021 Feb; 192(3):531-541. PubMed ID: 32583431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-chain multiple myeloma in a cat.
    Yamada O; Tamura K; Yagihara H; Isotani M; Azakami M; Sawada S; Ono K; Washizu T; Bonkobara M
    J Vet Diagn Invest; 2007 Jul; 19(4):443-7. PubMed ID: 17609361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feline lymphoplasmacytic stomatitis associated with monoclonal gammopathy and Bence-Jones proteinuria.
    Lyon KF
    J Vet Dent; 1994 Mar; 11(1):25-7. PubMed ID: 7993584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
    Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
    Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimodal immunoglobulin A gammopathy in a cat with feline myeloma-related disorders.
    Igase M; Shimokawa Miyama T; Kambayashi S; Shimoyama Y; Hiraoka H; Hirata Y; Iwata M; Baba K; Mizuno T; Okuda M
    J Vet Med Sci; 2016 May; 78(4):691-5. PubMed ID: 26638898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
    Ogawa Y; Suzuki K; Sakai A; Iida S; Ogura M; Tobinai K; Matsumoto M; Matsue K; Terui Y; Ohashi K; Ishii M; Mukai HY; Ando K; Hotta T
    Cancer Sci; 2013 Jul; 104(7):912-9. PubMed ID: 23574271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
    Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
    Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with central nervous system involvement in a cat.
    Appel SL; Moens NM; Abrams-Ogg AC; Woods JP; Nykamp S; Bienzle D
    J Am Vet Med Assoc; 2008 Sep; 233(5):743-7. PubMed ID: 18764709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Picot J; Cooper K; Bryant J; Clegg AJ
    Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
    Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M
    BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
    Mateos MV; Bringhen S; Richardson PG; Lahuerta JJ; Larocca A; Oriol A; Boccadoro M; García-Sanz R; Di Raimondo F; Esseltine DL; van de Velde H; Desai A; Londhe A; San Miguel JF; Palumbo A
    Haematologica; 2014 Jun; 99(6):1114-22. PubMed ID: 24763402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.